Compare $NVAX vs $VIR | Chartloom

Compare

$NVAX vs $VIR

Novavax Inc · Vir Biotechnology Inc

NVAX

Novavax Inc

VIR

Vir Biotechnology Inc

Compare $NVAX vs $VIR

Comparing Novavax Inc and Vir Biotechnology Inc

NVAXNovavax Inc

VIRVir Biotechnology Inc

NVAXNovavax Inc

Market cap

$2.10B

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

10.28x

Rev growth (TTM)

-61.6%

YTD performance

78.8%

52W performance

43.3%

FCF yield

-2.0%

VIRVir Biotechnology Inc

Market cap

$1.97B

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

36.09x

Rev growth (TTM)

1496.1%

YTD performance

97.0%

52W performance

93.4%

FCF yield

-10.3%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

NVAX

VIR

Detailed metrics comparison

NVAX

Novavax Inc

VIR

Vir Biotechnology Inc

Market Cap

NVAX$2.10B

VIR$1.97B

Enterprise Value

NVAX$2.20B

VIR$1.69B

Price

NVAX$12.75

VIR$11.70

P/E Ratio

NVAXN/A

VIRN/A

P/S Ratio

NVAX5.07x

VIR6.51x

EV/Sales

NVAX5.32x

VIR5.59x

EV/EBITDA

NVAX4.05x

VIR1.92x

P/B Ratio

NVAX45.86x

VIR1.92x

P/FCF Ratio

NVAXN/A

VIRN/A

EV/FCF

NVAX-51.40x

VIR-8.32x

PEG Ratio

NVAXN/A

VIRN/A

Forward P/E (NTM)

NVAXN/A

VIRN/A

Forward P/S (NTM)

NVAX10.28x

VIR36.09x

Revenue (TTM)

NVAX$414M

VIR$303M

Revenue Growth (YoY)

NVAX-61.6%

VIR1496.1%

Forward Rev Growth

NVAX-25.1%

VIR-58.9%

Gross Margin (TTM)

NVAX79.2%

VIR100.0%

Operating Margin (TTM)

NVAX0.0%

VIR0.0%

EBITDA Margin (TTM)

NVAX-24.0%

VIR-45.9%

Net Margin (TTM)

NVAX-59.9%

VIR-41.5%

FCF Margin (TTM)

NVAX-10.4%

VIR-67.1%

Net Income (TTM)

NVAX$-248M

VIR$-126M

FCF (TTM)

NVAX$-43M

VIR$-204M

EPS (TTM)

NVAX-$1.51

VIR-$0.75

ROE (TTM)

NVAX283.1%

VIR-1486.0%

ROA (TTM)

NVAX-2275.0%

VIR-1168.0%

ROIC (TTM)

NVAX40.0%

VIR-1486.0%

Cash

NVAX$191M

VIR$279M

Debt

NVAX$297M

VIR$0

Net Cash/Debt

NVAX$-106M

VIR$279M

Current Ratio (TTM)

NVAX2.33x

VIR6.04x

Quick Ratio (TTM)

NVAX2.23x

VIR5.69x

Debt/Equity (TTM)

NVAX6.07x

VIR0.00x

Debt/Assets (TTM)

NVAX0.0%

VIR0.0%

Interest Coverage (TTM)

NVAXN/A

VIRN/A

Net Debt/EBITDA (TTM)

NVAX0.00x

VIR0.00x

Beta

NVAX2.81

VIR1.77

52W Performance

NVAX43.3%

VIR93.4%

YTD Performance

NVAX78.8%

VIR97.0%

% from 52W High

NVAX-4.7%

VIR-2.6%

% from 52W Low

NVAX105.6%

VIR143.0%

Asset Turnover (TTM)

NVAX0.38x

VIR0.28x

FCF Yield (TTM)

NVAX-2.0%

VIR-10.3%

Earnings Yield (TTM)

NVAX-11.8%

VIR-6.4%

Dividend Yield (TTM)

NVAXN/A

VIRN/A

Rule of 40

NVAX-72.0

VIR1,428.9

EV/GP/RG

NVAXN/A

VIRN/A

Ticker research

View NVAX research View VIR research

Metric	NVAX Novavax Inc	VIR Vir Biotechnology Inc
Market & Valuation
Market Cap	$2.10B	$1.97B
Enterprise Value	$2.20B	$1.69B
Price	$12.75	$11.70
P/E Ratio	N/A	N/A
P/S Ratio	5.07x	6.51x
EV/Sales	5.32x	5.59x
EV/EBITDA	4.05x	1.92x
P/B Ratio	45.86x	1.92x
P/FCF Ratio	N/A	N/A
EV/FCF	-51.40x	-8.32x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	10.28x	36.09x
Revenue & Growth
Revenue (TTM)	$414M	$303M
Revenue Growth (YoY)	-61.6%	1496.1%
Forward Rev Growth	-25.1%	-58.9%
Profitability
Gross Margin (TTM)	79.2%	100.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-24.0%	-45.9%
Net Margin (TTM)	-59.9%	-41.5%
FCF Margin (TTM)	-10.4%	-67.1%
Net Income (TTM)	$-248M	$-126M
FCF (TTM)	$-43M	$-204M
EPS (TTM)	-$1.51	-$0.75
ROE (TTM)	283.1%	-1486.0%
ROA (TTM)	-2275.0%	-1168.0%
ROIC (TTM)	40.0%	-1486.0%
Financial Health
Cash	$191M	$279M
Debt	$297M	$0
Net Cash/Debt	$-106M	$279M
Current Ratio (TTM)	2.33x	6.04x
Quick Ratio (TTM)	2.23x	5.69x
Debt/Equity (TTM)	6.07x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	2.81	1.77
52W Performance	43.3%	93.4%
YTD Performance	78.8%	97.0%
% from 52W High	-4.7%	-2.6%
% from 52W Low	105.6%	143.0%
Efficiency & Yields
Asset Turnover (TTM)	0.38x	0.28x
FCF Yield (TTM)	-2.0%	-10.3%
Earnings Yield (TTM)	-11.8%	-6.4%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-72.0	1,428.9
EV/GP/RG	N/A	N/A
Ticker research	View NVAX research	View VIR research

Valuation

P/S Ratio

NVAX

5.07x

VIR

6.51x

EV/FCF

NVAX

-51.40x

VIR

-8.32x

Growth & revenue

Revenue Growth TTM

VIR

1496.1%

NVAX

-61.6%

Forward Revenue Growth

NVAX

-25.1%

VIR

-58.9%

Profitability & performance

Gross Margin

VIR

100.0%

NVAX

79.2%

ROE

NVAX

283.1%

VIR

-1486.0%

FCF Yield %

NVAX

-2.0%

VIR

-10.3%

52-Week Performance

VIR

93.4%

NVAX

43.3%

Detailed metrics comparison

NVAX

Novavax Inc

VIR

Vir Biotechnology Inc

Market Cap

NVAX$2.10B

VIR$1.97B

Enterprise Value

NVAX$2.20B

VIR$1.69B

Price

NVAX$12.75

VIR$11.70

P/E Ratio

NVAXN/A

VIRN/A

P/S Ratio

NVAX5.07x

VIR6.51x

EV/Sales

NVAX5.32x

VIR5.59x

EV/EBITDA

NVAX4.05x

VIR1.92x

P/B Ratio

NVAX45.86x

VIR1.92x

P/FCF Ratio

NVAXN/A

VIRN/A

EV/FCF

NVAX-51.40x

VIR-8.32x

PEG Ratio

NVAXN/A

VIRN/A

Forward P/E (NTM)

NVAXN/A

VIRN/A

Forward P/S (NTM)

NVAX10.28x

VIR36.09x

Revenue (TTM)

NVAX$414M

VIR$303M

Revenue Growth (YoY)

NVAX-61.6%

VIR1496.1%

Forward Rev Growth

NVAX-25.1%

VIR-58.9%

Gross Margin (TTM)

NVAX79.2%

VIR100.0%

Operating Margin (TTM)

NVAX0.0%

VIR0.0%

EBITDA Margin (TTM)

NVAX-24.0%

VIR-45.9%

Net Margin (TTM)

NVAX-59.9%

VIR-41.5%

FCF Margin (TTM)

NVAX-10.4%

VIR-67.1%

Net Income (TTM)

NVAX$-248M

VIR$-126M

FCF (TTM)

NVAX$-43M

VIR$-204M

EPS (TTM)

NVAX-$1.51

VIR-$0.75

ROE (TTM)

NVAX283.1%

VIR-1486.0%

ROA (TTM)

NVAX-2275.0%

VIR-1168.0%

ROIC (TTM)

NVAX40.0%

VIR-1486.0%

Cash

NVAX$191M

VIR$279M

Debt

NVAX$297M

VIR$0

Net Cash/Debt

NVAX$-106M

VIR$279M

Current Ratio (TTM)

NVAX2.33x

VIR6.04x

Quick Ratio (TTM)

NVAX2.23x

VIR5.69x

Debt/Equity (TTM)

NVAX6.07x

VIR0.00x

Debt/Assets (TTM)

NVAX0.0%

VIR0.0%

Interest Coverage (TTM)

NVAXN/A

VIRN/A

Net Debt/EBITDA (TTM)

NVAX0.00x

VIR0.00x

Beta

NVAX2.81

VIR1.77

52W Performance

NVAX43.3%

VIR93.4%

YTD Performance

NVAX78.8%

VIR97.0%

% from 52W High

NVAX-4.7%

VIR-2.6%

% from 52W Low

NVAX105.6%

VIR143.0%

Asset Turnover (TTM)

NVAX0.38x

VIR0.28x

FCF Yield (TTM)

NVAX-2.0%

VIR-10.3%

Earnings Yield (TTM)

NVAX-11.8%

VIR-6.4%

Dividend Yield (TTM)

NVAXN/A

VIRN/A

Rule of 40

NVAX-72.0

VIR1,428.9

EV/GP/RG

NVAXN/A

VIRN/A

Ticker research

View NVAX research View VIR research

Metric	NVAX Novavax Inc	VIR Vir Biotechnology Inc
Market & Valuation
Market Cap	$2.10B	$1.97B
Enterprise Value	$2.20B	$1.69B
Price	$12.75	$11.70
P/E Ratio	N/A	N/A
P/S Ratio	5.07x	6.51x
EV/Sales	5.32x	5.59x
EV/EBITDA	4.05x	1.92x
P/B Ratio	45.86x	1.92x
P/FCF Ratio	N/A	N/A
EV/FCF	-51.40x	-8.32x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	10.28x	36.09x
Revenue & Growth
Revenue (TTM)	$414M	$303M
Revenue Growth (YoY)	-61.6%	1496.1%
Forward Rev Growth	-25.1%	-58.9%
Profitability
Gross Margin (TTM)	79.2%	100.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-24.0%	-45.9%
Net Margin (TTM)	-59.9%	-41.5%
FCF Margin (TTM)	-10.4%	-67.1%
Net Income (TTM)	$-248M	$-126M
FCF (TTM)	$-43M	$-204M
EPS (TTM)	-$1.51	-$0.75
ROE (TTM)	283.1%	-1486.0%
ROA (TTM)	-2275.0%	-1168.0%
ROIC (TTM)	40.0%	-1486.0%
Financial Health
Cash	$191M	$279M
Debt	$297M	$0
Net Cash/Debt	$-106M	$279M
Current Ratio (TTM)	2.33x	6.04x
Quick Ratio (TTM)	2.23x	5.69x
Debt/Equity (TTM)	6.07x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	2.81	1.77
52W Performance	43.3%	93.4%
YTD Performance	78.8%	97.0%
% from 52W High	-4.7%	-2.6%
% from 52W Low	105.6%	143.0%
Efficiency & Yields
Asset Turnover (TTM)	0.38x	0.28x
FCF Yield (TTM)	-2.0%	-10.3%
Earnings Yield (TTM)	-11.8%	-6.4%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-72.0	1,428.9
EV/GP/RG	N/A	N/A
Ticker research	View NVAX research	View VIR research